H. Lundbeck A/S- (OTCMKTS:HLUYY) and Gilla (OTCMKTS:GLLA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.
This is a breakdown of recent ratings and target prices for H. Lundbeck A/S- and Gilla, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|H. Lundbeck A/S-||2||1||1||0||1.75|
This table compares H. Lundbeck A/S- and Gilla’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|H. Lundbeck A/S-||20.91%||38.08%||22.72%|
Insider & Institutional Ownership
0.1% of H. Lundbeck A/S- shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
H. Lundbeck A/S- pays an annual dividend of $0.95 per share and has a dividend yield of 2.1%. Gilla does not pay a dividend. H. Lundbeck A/S- pays out 37.8% of its earnings in the form of a dividend.
Earnings & Valuation
This table compares H. Lundbeck A/S- and Gilla’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|H. Lundbeck A/S-||$2.62 billion||3.43||$398.58 million||$2.51||17.95|
|Gilla||$4.60 million||0.63||-$6.64 million||N/A||N/A|
H. Lundbeck A/S- has higher revenue and earnings than Gilla.
Risk & Volatility
H. Lundbeck A/S- has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500. Comparatively, Gilla has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.
H. Lundbeck A/S- beats Gilla on 9 of the 11 factors compared between the two stocks.
About H. Lundbeck A/S-
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for treating symptomatic neurogenic orthostatic hypotension; Onfi for Lennox-Gastaut syndrome; and Rexulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. H. Lundbeck A/S was founded in 1915 and is headquartered in Valby, Denmark.
Gilla Inc. engages in the manufacture, marketing, and distribution of generic and premium branded e-liquid used in vaporizers, electronic cigarettes, and other vaping hardware and accessories in Europe, Canada, and the United States. The company offers its products under the brand names of Spectrum Concentrates, Coil Glaze, Craft Vapes, Siren, The Drip Factory, Shake It, Surf Sauce, Ohana, Moshi, Crisp, Just Fruit, Vinto Vape, Vapor's Dozen, Enriched Vapor, and Crown E-liquid. Gilla Inc. sells its products through market channels, including vape shops, retail and wholesale distributors, convenience stores, and e-commerce Websites. The company is headquartered in Daytona Beach, Florida.
Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.